Analyst firms · Piper Sandler · CL
Piper Sandler CL price target and rating history
Colgate-Palmolive Company (CL) · Consumer Discretionary
Piper Sandler rates Colgate-Palmolive Company (CL) Overweight with a $88 price target, as of its latest action on Jan 7, 2026. It has published 3 rating actions on CL since September 2024, including 1 upgrade and 0 downgrades. Across 7 firms with a CL price target in the last 12 months, the median target is $88. Piper Sandler's target matches it.
- Current rating
- Overweight
- Price target
- $88
- Median target, all firms
- $88
- Actions on CL
- 3
Piper Sandler price target on CL
Every Piper Sandler rating on CL
- Jan 7, 2026
- Oct 3, 2025
- Sep 24, 2024
How other firms rate CL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Bernstein | Mkt Perform | $96 | Jun 12, 2026 |
| Rothschild & Co Redburn | Buy | $100 | Apr 21, 2026 |
| TD Cowen | Hold | $85 | Mar 31, 2026 |
| Deutsche Bank | Buy | $98 | Mar 30, 2026 |
| Wells Fargo | Equal Weight | $86 | Jan 13, 2026 |
| Piper Sandler | Overweight | $88 | Jan 7, 2026 |
| Argus Research | Hold | Dec 11, 2025 | |
| RBC Capital Markets | Outperform | $88 | Dec 9, 2025 |
Questions about Piper Sandler and CL
- What is Piper Sandler's price target for CL?
- Piper Sandler's latest stated price target for Colgate-Palmolive Company (CL) is $88, from its action on Jan 7, 2026.
- What is Piper Sandler's rating on CL?
- Piper Sandler rates CL Overweight, a bullish rating, as of Jan 7, 2026.
- When did Piper Sandler last change its view on CL?
- On Jan 7, 2026, Piper Sandler upgrades to Overweight from Neutral, price target $88.
- How does Piper Sandler's CL target compare with other analysts?
- Across 7 firms with a CL price target in the last 12 months, the median target is $88. Piper Sandler's target matches it.
More CL rating histories
All Piper Sandler ratingsCL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.